Two residues apart

In 1953 Vincent du Vigneaud synthesized oxytocin — the first peptide hormone ever made in a lab, the work that won a Nobel Prize — and then did the same for vasopressin. The two molecules turned out to be almost the same object: nine amino acids each, the same disulfide ring, both released from the posterior pituitary. They differ at exactly two positions, the third residue and the eighth. Two substitutions out of nine.

And yet they share almost nothing in what they do. Oxytocin drives labor, milk let-down, and the social-bonding story this site has told elsewhere. Vasopressin runs water balance and blood pressure. Same scaffold, two swapped residues, and the result is two hormones on opposite sides of physiology — the cleanest demonstration in the body that peptide specificity is written in small sequence differences, not in size. This is the quieter twin’s story, and the twist is that the quieter one became by far the more useful drug. Bullish on the science, sceptical on the page.

Vasopressin is the body’s water manager. Specialized osmoreceptors in the hypothalamus sense when the blood is becoming too concentrated, and vasopressin is released in response. Its effects then split cleanly by receptor. At V2 receptors on the kidney’s collecting ducts, it inserts aquaporin water channels into the cell membrane, so water is reabsorbed and the urine turns concentrated — the antidiuretic effect that gives the hormone its other name, ADH. At V1a receptors on blood vessels, it causes constriction, raising blood pressure. A third subtype, V1b, sits on the pituitary and contributes to the stress response.

That receptor split is the whole key to the pharmacology. One hormone with three jobs — hold water, tighten vessels, assist the stress axis — means a drug can be built to pick just one of them. Nearly every vasopressin medicine is exactly that: a molecule tuned to a single receptor subtype, so it does one of the hormone’s jobs without the others.

The axis is easiest to read through its two failures. Too little effective vasopressin, and the kidney cannot hold water: this is diabetes insipidus, which has nothing to do with sugar and everything to do with torrents of dilute urine and relentless thirst — whether because the pituitary makes too little hormone (central) or the kidney cannot hear it (nephrogenic). Too much vasopressin, and the opposite happens: the body retains water it should shed, diluting the blood’s sodium. That is the syndrome of inappropriate ADH, SIADH, and its danger is hyponatremia.

Those two poles — water lost, water trapped — are exactly the handles the drugs grab. Replace the missing signal at one end; block the excess at the other. Where oxytocin’s therapeutic story is mostly a single difficult idea, vasopressin’s is a whole shelf.

Desmopressin (DDAVP) is vasopressin rebuilt to hit V2 and little else — longer-acting than the natural hormone, and stripped of the pressor effect. That single-receptor focus explains a startling spread of uses. It replaces the missing hormone in central diabetes insipidus. It curbs overnight urine in bedwetting. And — the surprise — it treats von Willebrand disease and mild hemophilia A, because V2 activation also releases clotting factors (von Willebrand factor and factor VIII) stored in the vessel wall. Three unrelated-looking indications, one receptor underneath.

The vaptans run the opposite way: tolvaptan and conivaptan block V2, so the kidney dumps free water without dumping electrolytes — “aquaretics.” In the SALT trials, the oral V2 antagonist tolvaptan corrected the low sodium of hyponatremia (Schrier et al., NEJM, 2006), and the same drug later found a second life slowing polycystic kidney disease. And vasopressin itself, used for its V1a arm, is a vasopressor in the ICU — though the honest record keeps it modest: in septic shock it did not beat standard norepinephrine on mortality (Russell et al., NEJM, 2008). Replace the signal, block the signal, or borrow its pressor arm — three receptor strategies, one hormone.

Vasopressin does have a brain life, and in animals it is genuinely dramatic. In prairie voles — a rare monogamous rodent — the V1a receptor is central to male pair-bonding, and in a landmark experiment, transferring the V1aR gene into the ventral forebrain of a promiscuous vole species increased its preference for a familiar partner (Lim et al., Nature, 2004). Across species, vasopressin shapes social recognition, territoriality and aggression, often as the more male-weighted counterpart to oxytocin.

But this is exactly where the discipline the oxytocin story demands has to carry over. A vole is not a person; a bonding effect in a rodent forebrain is not a human therapy; and the human behavioral pharmacology built on this remains thin and inconsistent. Vasopressin’s proven drugs act on the nephron and the arteriole, not on affiliation. The behavior arm is real biology and, so far, a poor drug target — the same shape of honest verdict the love-hormone hype earned.

Put the two side by side and the lesson is almost literary. Oxytocin got the fame, the nickname, and the sprays that mostly didn’t work. Vasopressin, its two-residue sibling, got the quiet shelf of medicines that do — a water-balance pharmacopoeia spun out of a single nine-amino-acid hormone by choosing, each time, which receptor to grip. Two swapped residues decided which twin became a legend and which became a drug cabinet, and the one that reads less romantic is the one you are far more likely to actually be prescribed.

• Two residues, opposite physiology. Vasopressin and oxytocin are nine-residue twins differing at positions 3 and 8. Those two swaps route them to different receptors — water and vessels vs labor and bonding.
• The receptor split is the pharmacology. V2 (kidney, water), V1a (vessels, pressor), V1b (pituitary, stress). Nearly every vasopressin drug grips just one subtype.
• Read the axis through its failures. Too little effective ADH → diabetes insipidus (dilute urine, thirst); too much → SIADH and hyponatremia. The drugs grab exactly those handles.
• A whole shelf of real drugs. Desmopressin (V2: diabetes insipidus, bedwetting, and — via clotting-factor release — von Willebrand disease); the vaptans (V2 block: hyponatremia, ADPKD); vasopressin itself (V1a pressor in shock, though it didn't beat norepinephrine).
• The behavior arm is real but a poor drug target. V1a drives vole pair-bonding and social behavior, but human behavioral therapeutics stay thin — the same honest verdict the oxytocin hype earned.